We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
CREBBP/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells.
- Authors
Bommi-Reddy, Archana; Park-Chouinard, Sungmi; Mayhew, David N.; Terzo, Esteban; Hingway, Aparna; Steinbaugh, Michael J.; Wilson, Jonathan E.; Sims III, Robert J.; Conery, Andrew R.
- Abstract
Therapeutic targeting of the estrogen receptor (ER) is a clinically validated approach for estrogen receptor positive breast cancer (ER+ BC), but sustained response is limited by acquired resistance. Targeting the transcriptional coactivators required for estrogen receptor activity represents an alternative approach that is not subject to the same limitations as targeting estrogen receptor itself. In this report we demonstrate that the acetyltransferase activity of coactivator paralogs CREBBP/EP300 represents a promising therapeutic target in ER+ BC. Using the potent and selective inhibitor CPI-1612, we show that CREBBP/EP300 acetyltransferase inhibition potently suppresses in vitro and in vivo growth of breast cancer cell line models and acts in a manner orthogonal to directly targeting ER. CREBBP/EP300 acetyltransferase inhibition suppresses ER-dependent transcription by targeting lineage-specific enhancers defined by the pioneer transcription factor FOXA1. These results validate CREBBP/EP300 acetyltransferase activity as a viable target for clinical development in ER+ breast cancer.
- Subjects
CANCER cells; GENE enhancers; HORMONE receptor positive breast cancer; ACETYLTRANSFERASES; BREAST cancer; ESTROGEN receptors
- Publication
PLoS ONE, 2022, Vol 17, Issue 3, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0262378